However, it is worth mentioning that the substantial progress in prostate cancer survival may be influenced by lead-time bias due to the indiscriminate use of prostate-specific antigen (PSA) testing during the study period, which likely artificially prolonged survival [72]. The gene discussed is KLK3; the disease is prostate cancer.